ArticleFrontiers in aging neuroscience2025
Influence of diabetes on the efficacy of DL-3-n-butylphthalide in post-stroke cognitive impairment: a 12-month prospective cohort study.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of N-butylphthalide treatment with 1-year activities-of-daily-living recovery in convalescent ischemic stroke patients with chronic disease burden: a post-marketing real-world non-randomized controlled study.Frontiers in medicine · 2026Trial
- Stratified Efficacy and Peripheral Neuroinflammatory Mechanisms of Jin's Tongue Triple Acupuncture as Adjunctive Therapy for Subacute Post-Stroke Broca Aphasia: A 1:1 PSM Retrospective Cohort Study.Journal of molecular neuroscience : MN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Diabetic chronic hyperglycaemia amplifies oxidative stress, microvascular injury, and insulin-resistant neuroinflammation, counteracting the pro-angiogenic, mitochondrial-protective, and anti-apoptotic effects of DL-3-n-butylphthalide (NBP). It remains unknown whether glycaemic status modulates the long-term cognitive benefits of NBP after ischaemic stroke (IS). This study compared 12-month efficacy of NBP on cognition between non-diabetic and diabetic patients with subacute IS. Methods: We conducted a community-based prospective cohort study involving 594 patients who had an ischemic stroke 1-6 months prior and no baseline cognitive impairment. Participants were assigned to either the NBP treatment group or the usual care group. MMSE scores were assessed at baseline and 12 months. The primary outcomes were ΔMMSE, its percentage change, and incident cognitive decline (≥3-point MMSE reduction). Separate multivariable regression analyses were conducted for non-diabetic and diabetic subgroups. Results: In non-diabetic patients ( Conclusion: In non-diabetic patients with subacute IS, NBP exerts more pronounced protective effects on overall cognition and language. In contrast, in diabetic patients, only a slight improvement in orientation is observed. Clinically, it is essential to prioritize optimization of diabetes management based on blood glucose control status before considering the addition of NBP. Further validation of these exploratory findings is warranted through larger-scale randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.